A newly approved drug, sotagliflozin, has shown significant benefits in reducing heart attacks and strokes for people with type 2 diabetes and kidney disease. A study published in The Lancet Diabetes & Endocrinology highlights the drug’s unique cardiovascular advantages, making it a promising new option for patients with chronic conditions. Sotagliflozin’s Breakthrough Benefits Sotagliflozin, commercially …
Continue reading “New Diabetes Drug Significantly Reduces Heart Attack and Stroke Risk”